{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:23:50Z","timestamp":1648970630964},"reference-count":187,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.cger.2011.12.002","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T12:49:41Z","timestamp":1328878181000},"page":"115-152","source":"Crossref","is-referenced-by-count":0,"title":["Liquid Tumors in the Elderly"],"prefix":"10.1016","volume":"28","author":[{"given":"Anthony","family":"Mato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V60.2.309.309","article-title":"Causes of initial remission induction failure in acute myelogenous leukemia","volume":"60","author":"Estey","year":"1982","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","article-title":"Acute myeloid leukaemia in the elderly: a review","volume":"152","author":"Pollyea","year":"2011","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.cger.2011.12.002_bib4","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cger.2011.12.002_bib5","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cger.2011.12.002_bib6","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib8","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2006.06403.x","article-title":"Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial","volume":"136","author":"van der Holt","year":"2007","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.cger.2011.12.002_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cger.2011.12.002_bib11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Valk","year":"2004","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cger.2011.12.002_bib12","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1200\/JCO.2005.04.5450","article-title":"Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization","volume":"24","author":"Rucker","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.cger.2011.12.002_bib13","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","article-title":"Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group","volume":"28","author":"Haferlach","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2010-09-191312","article-title":"The prognostic and functional role of microRNAs in acute myeloid leukemia","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.leu.2402809","article-title":"Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia","volume":"17","author":"Larson","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","article-title":"Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720","volume":"100","author":"Baer","year":"2002","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.cger.2011.12.002_bib17","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2010-04-277269","article-title":"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999","volume":"116","author":"Cripe","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cger.2011.12.002_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.1998.16.3.872","volume":"16","author":"Lowenberg","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V79.2.313.313","article-title":"Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia","volume":"79","author":"Wiernik","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib21","first-page":"126","article-title":"Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia","volume":"83","author":"Ferrara","year":"1998","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","article-title":"A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group","volume":"103","author":"Rowe","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cger.2011.12.002_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2009.07604.x","article-title":"The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial","volume":"145","author":"Burnett","year":"2009","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.cger.2011.12.002_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199709042501","article-title":"Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia","volume":"25","author":"Schiller","year":"1997","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2008.04.013","article-title":"Acute myeloid leukemia in the elderly","volume":"35","author":"Dombret","year":"2008","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2008-0224","article-title":"Acute myelogenous leukemia in older adults","volume":"14","author":"Klepin","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.cger.2011.12.002_bib29","first-page":"20","article-title":"Treating the \u201colder\u201d adult with acute lymphoblastic leukemia","volume":"13","author":"Marks","year":"2010","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.cger.2011.12.002_bib30","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2003.09.110","article-title":"Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia","volume":"21","author":"Bertz","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","article-title":"Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival","volume":"26","author":"Valcarcel","year":"2008","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.cger.2011.12.002_bib32","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2005-11-4354","article-title":"Cancer and Leukemia Group B 8461","volume":"108","author":"Farag","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","article-title":"A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial","volume":"116","author":"Rollig","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib36","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood-2010-11-321737","article-title":"Most 70- to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment","volume":"117","author":"Juliusson","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib37","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.cger.2011.12.002_bib38","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.bjc.6605922","article-title":"Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types","volume":"103","author":"Green","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/13543784.2011.542750","article-title":"Vorinostat in acute myeloid leukemia and myelodysplastic syndromes","volume":"20","author":"Prebet","year":"2011","journal-title":"Expert Opin Invest Drugs"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.leukres.2010.11.006","article-title":"Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival","volume":"35","author":"Tickenbrock","year":"2011","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","article-title":"Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.18632\/oncotarget.290","article-title":"Targeting mTOR for the treatment of AML","volume":"2","author":"Altman","year":"2011","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.cger.2011.12.002_bib45","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.4161\/cc.8.23.10091","article-title":"Targeting translation in acute myeloid leukemia: a new paradigm for therapy?","volume":"8","author":"Tamburini","year":"2009","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11912-009-0047-x","article-title":"New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines","volume":"11","author":"Fathi","year":"2009","journal-title":"Curr Oncol Reports"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2010.032680","article-title":"The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine","volume":"96","author":"Walsby","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cger.2011.12.002_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-8722-3-17","article-title":"Novel agents and regimens for acute myeloid leukemi: 2009 ASH annual meeting highlights","volume":"3","author":"Zhu","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.cger.2011.12.002_bib49","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib50","doi-asserted-by":"crossref","first-page":"182833","DOI":"10.1182\/blood-2010-07-297143","article-title":"A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia","volume":"117","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cger.2011.12.002_bib51","series-title":"Adult acute lymphocytic leukemia","first-page":"97","article-title":"The generalized care of the patient with acute lymphoblastic leukemia","author":"Mato","year":"2011"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib52","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cger.2011.12.002_bib53","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cger.2011.12.002_bib54","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib55","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1080\/10428190802517732","article-title":"Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia","volume":"49","author":"Chang","year":"2008","journal-title":"Leukemia Lymphoma"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib56","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib57","first-page":"600","article-title":"Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl","year":"2009","journal-title":"Clin Advance Hematol Oncol"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","article-title":"High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis","volume":"22","author":"Patel","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3324\/haematol.2009.015974","article-title":"Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"95","author":"Fielding","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11899-010-0061-y","article-title":"Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"5","author":"Ohno","year":"2010","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib61","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11899-996-0006-7","article-title":"Japan Adult Leukemia Study, Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy","volume":"1","author":"Ravandi","year":"2006","journal-title":"Curr Hematol Malignancy Reports"},{"key":"10.1016\/j.cger.2011.12.002_bib62","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology:118\u201322.","DOI":"10.1182\/asheducation-2005.1.118"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib63","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib64","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cger.2011.12.002_bib65","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib66","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2007-12-128918","article-title":"Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cncr.22406","article-title":"Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta-analysis","volume":"109","author":"Bartolozzi","year":"2007","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.cger.2011.12.002_bib68","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2008-10-184093","article-title":"Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation","volume":"113","author":"Bachanova","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib69","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.cger.2011.12.002_bib70","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib71","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cger.2011.12.002_bib72","doi-asserted-by":"crossref","unstructured":"Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21(9):190714.","DOI":"10.1038\/sj.leu.2404824"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib73","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematolo Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib74","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"6 Suppl 5","key":"10.1016\/j.cger.2011.12.002_bib75","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2007.11.002","article-title":"Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine","volume":"34","author":"Larson","year":"2007","journal-title":"Semin Oncol"},{"issue":"26","key":"10.1016\/j.cger.2011.12.002_bib76","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1182\/blood-2010-01-262006","article-title":"A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL","volume":"116","author":"Nijmeijer","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib77","first-page":"168","article-title":"Rituximab as therapy for acute lymphoblastic leukemia","volume":"8","author":"Thomas","year":"2010","journal-title":"Clin Advance Hematol Oncol"},{"issue":"24","key":"10.1016\/j.cger.2011.12.002_bib78","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib79","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2007.06760.x","article-title":"A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases","volume":"139","author":"Parnes","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib81","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/cncr.21901","article-title":"Activity of alemtuzumab in patients with CD52-positive acute leukemia","volume":"106","author":"Tibes","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib82","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib83","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","article-title":"Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells","volume":"106","author":"Avellino","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cger.2011.12.002_bib84","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/0008-5472.CAN-08-4884","article-title":"Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia","volume":"69","author":"Chiarini","year":"2009","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.cger.2011.12.002_bib85","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","article-title":"Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia","volume":"70","author":"Chiarini","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.cger.2011.12.002_bib86","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3109\/10428194.2011.564696","article-title":"NOTCH and phosphatidylinositide 3-kinase\/phosphatase and tensin homolog deleted on chromosome ten\/AKT\/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia","volume":"52","author":"Guo","year":"2011","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib87","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","article-title":"Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor","volume":"33","author":"Hirase","year":"2009","journal-title":"Leukemia Res"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2010.026997","article-title":"The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia","volume":"96","author":"Saunders","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib89","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1084\/jem.20081561","article-title":"Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1","volume":"205","author":"Li","year":"2008","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib90","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2007.06527.x","article-title":"In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia","volume":"137","author":"Beesley","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib91","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/pbc.21386","article-title":"Flavopiridol displays preclinical activity in acute lymphoblastic leukemia","volume":"50","author":"Jackman","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.cger.2011.12.002_bib92","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1158\/1078-0432.CCR-05-1201","article-title":"Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias","volume":"11","author":"Karp","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib93","first-page":"307","article-title":"Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial","volume":"9","author":"Karp","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.cger.2011.12.002_bib94","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib95","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.20.2.494","article-title":"Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clinl Oncol"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib96","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2009.25.9978","article-title":"Detecting disabilities in older patients with cancer: comparison between Comprehensive Geriatric Assessment and Vulnerable Elders Survey-13","volume":"28","author":"Luciani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib97","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib98","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.critrevonc.2006.11.001","article-title":"Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale","volume":"61","author":"Wedding","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib99","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3816\/CLM.2006.n.041","article-title":"Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures","volume":"7","author":"Siegel","year":"2006","journal-title":"Clin Lymphoma, Myeloma Leukemia"},{"key":"10.1016\/j.cger.2011.12.002_bib101","first-page":"3124","article-title":"Multicenter Analysis of 150 very elderly non-hodgkin's lymphoma (nhl) patients: impact of comorbidities and response to initial therapy on survival","volume":"116","author":"Evens","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.cger.2011.12.002_bib102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"7247","key":"10.1016\/j.cger.2011.12.002_bib103","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"7277","key":"10.1016\/j.cger.2011.12.002_bib104","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","article-title":"Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response","volume":"105","author":"Monti","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the miolecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cger.2011.12.002_bib107","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangement are associated with a poor porgosis in ndiffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib108","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","article-title":"The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.cger.2011.12.002_bib109","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.cger.2011.12.002_bib110","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib111","first-page":"3441","volume":"110","author":"Tucci","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.cger.2011.12.002_bib112","first-page":"2684","article-title":"Comprehensive Geriatric assessment-adapted chemotherapy in elderly patients (>70 years) with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): final results and long term follow-up","volume":"114","author":"Tirelli","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib113","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab compared with CHOP alone in Elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cger.2011.12.002_bib114","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP Study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib115","first-page":"205","article-title":"Six vs. eight cycles of bi-weekly CHOP-14 with or without Rituximab for elderly patients with diffuse large b-cell lymphoma (dlbcl): results of the completed RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"108","author":"Pfreundschuh","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib116","first-page":"584","article-title":"The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) for elderly patients with DLBCL","volume":"112","author":"Pfreundschuh","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"19","key":"10.1016\/j.cger.2011.12.002_bib117","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.cger.2011.12.002_bib118","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.cger.2011.12.002_bib119","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.cger.2011.12.002_bib120","first-page":"3561","article-title":"Autologous stem cell transplantation is feasible and of potential benefit in very elderly patients with lymphoma and limited comorbidities","volume":"116","author":"Elstrom","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"10.1016\/j.cger.2011.12.002_bib121","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bbmt.2009.12.537","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age","volume":"16","author":"Koreth","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib122","article-title":"High dose therapy (HDCT) with autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma in the elderly: feasibility of a patient-tailored treatment plan","volume":"104","author":"Rupolo","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"10.1016\/j.cger.2011.12.002_bib123","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","article-title":"Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-hodgkin lymphoma","volume":"14","author":"Wildes","year":"2008","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib124","article-title":"Comparison of outcomes in elderly patients with non-Hodgkins lymphoma undergoing high-dose chemotherapy to their younger counterparts: greater morbidity but no significant impact on overall survival","volume":"106","author":"Wildes","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"10.1016\/j.cger.2011.12.002_bib125","first-page":"1793","article-title":"Final results of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL)","volume":"116","author":"Hamlin","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib126","first-page":"4765","article-title":"A phase II trial of CHOP chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for Previously untreated elderly diffuse large B-cell lymphoma (DLBCL) patients","volume":"106","author":"Zinzani","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"17","key":"10.1016\/j.cger.2011.12.002_bib127","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib129","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.humpath.2008.10.007","article-title":"Epstein-Barr virus\u2013positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype","volume":"40","author":"Gibson","year":"2009","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2009.07.024","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations","volume":"41","author":"Hoeller","year":"2010","journal-title":"Hum Pathol"},{"issue":"22","key":"10.1016\/j.cger.2011.12.002_bib131","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.cger.2011.12.002_bib132","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1002\/cncr.25363","article-title":"Characteristics and outcomes of elderly patients with primary central nervous system lymphoma","volume":"116","author":"Ney","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib133","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1212\/01.wnl.0000300671.37279.0e","article-title":"Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation","volume":"70","author":"Gerstner","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib134","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2008","journal-title":"Neuro Oncol"},{"issue":"9700","key":"10.1016\/j.cger.2011.12.002_bib135","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.cger.2011.12.002_bib136","article-title":"Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: Results of CALGB 50202","volume":"116","author":"Rubenstein","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib137","first-page":"934","article-title":"Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide","volume":"64","author":"Enting","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib138","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","article-title":"Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma","volume":"86","author":"Voloschin","year":"2008","journal-title":"J Neuro-Oncol"},{"issue":"22","key":"10.1016\/j.cger.2011.12.002_bib139","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/annonc\/mdl379","article-title":"Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group","volume":"18","author":"Klimm","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cger.2011.12.002_bib141","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.283.283","article-title":"Results of a pivotal phase 2 study of brentuximab vedotin (sgn-35) in patients with relapsed or refractory Hodgkin lymphoma","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib142","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.cger.2011.12.002_bib143","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cger.2011.12.002_bib144","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.cger.2011.12.002_bib145","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as First-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib147","volume":"108","author":"Buske","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.cger.2011.12.002_bib148","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood (Annual Meeting abstracts)"},{"key":"10.1016\/j.cger.2011.12.002_bib149","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","author":"Salles","year":"2010","journal-title":"Asco Annual meeting"},{"key":"10.1016\/j.cger.2011.12.002_bib150","article-title":"Extended follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) shows durable benefit of 90 y-ibritumomab tiuxetan (zevalin(r)) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma","volume":"112","author":"Morschhauser","year":"2008","journal-title":"Blood (Annual Meeting Abstracts)"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib151","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.cger.2011.12.002_bib152","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"10.1016\/j.cger.2011.12.002_bib153","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib154","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"Blade","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib156","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.cger.2011.12.002_bib157","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.cger.2011.12.002_bib158","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cger.2011.12.002_bib159","series-title":"SEER Cancer Statistics Review","year":"1975"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib160","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2007-07-101212","article-title":"Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial","volume":"111","author":"Abdelkefi","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib161","first-page":"442","article-title":"Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood","volume":"18","author":"To","year":"1990","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib162","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","article-title":"Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma","volume":"31","author":"Jantunen","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib163","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1703240","article-title":"DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma","volume":"28","author":"Lazzarino","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib164","first-page":"108","article-title":"Mobilization of circulating progenitor cells in multiple myeloma during VCAD therapy with or without rhG-CSF","volume":"80","author":"Majolino","year":"1995","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.cger.2011.12.002_bib165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.bmt.1705308","article-title":"The VAD chemotherapy regimen plus a G-CSF dose of 10 microg\/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg\/kg for progenitor cell mobilization: results from a monocentric study of 82 patients","volume":"37","author":"Lefrere","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib166","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib167","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ cells in elderly patients (>\/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.cger.2011.12.002_bib168","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cger.2011.12.002_bib169","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2009-09-241737","article-title":"Melphalan 200 mg\/m(2) versus melphalan 100 mg\/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study","volume":"115","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cger.2011.12.002_bib170","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged >\/=70 years with multiple myeloma","author":"Bashir","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib171","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib172","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cger.2011.12.002_bib173","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.cger.2011.12.002_bib174","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cger.2011.12.002_bib176","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cger.2011.12.002_bib177","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.cger.2011.12.002_bib178","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jagannath S, Jakubowiak AJ, et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patiens with relapsed and relapsed\/refractory multiple myeloma: updated efficacy and safety data after > 2 years of follow-up. Blood (ASH Annual Meeting Abstracts);116:Abstract 3049.","DOI":"10.1182\/blood.V116.21.3049.3049"},{"issue":"10","key":"10.1016\/j.cger.2011.12.002_bib179","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.cger.2011.12.002_bib180","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cger.2011.12.002_bib181","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cger.2011.12.002_bib182","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.cger.2011.12.002_bib183","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cger.2011.12.002_bib184","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.cger.2011.12.002_bib185","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cger.2011.12.002_bib186","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cger.2011.12.002_bib187","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069011000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069011000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T04:59:15Z","timestamp":1593665955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069011000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":187,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0749069011000851"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2011.12.002","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}